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Abstract
Ectodermal dysplasias (EDs) are a large and heterogeneous group of hereditary disorders characterized by abnormalities in
structures of ectodermal origin. Incontinentia pigmenti (IP) is an ED characterized by skin lesions evolving over time, as well
as dental, nail, and ocular abnormalities. Due to X-linked dominant inheritance IP symptoms can only be seen in female
individuals while affected males die during development in utero. We observed a family of horses, in which several mares
developed signs of a skin disorder reminiscent of human IP. Cutaneous manifestations in affected horses included the
development of pruritic, exudative lesions soon after birth. These developed into wart-like lesions and areas of alopecia with
occasional wooly hair re-growth. Affected horses also had streaks of darker and lighter coat coloration from birth. The
observation that only females were affected together with a high number of spontaneous abortions suggested an X-linked
dominant mechanism of transmission. Using next generation sequencing we sequenced the whole genome of one affected
mare. We analyzed the sequence data for non-synonymous variants in candidate genes and found a heterozygous nonsense
variant in the X-chromosomal IKBKG gene (c.184C.T; p.Arg62*). Mutations in IKBKG were previously reported to cause IP in
humans and the homologous p.Arg62* variant has already been observed in a human IP patient. The comparative data thus
strongly suggest that this is also the causative variant for the observed IP in horses. To our knowledge this is the first large
animal model for IP.
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Introduction
Ectodermal dysplasias (EDs) are a large and heterogeneous
group of hereditary disorders characterized by abnormalities in
multiple structures of ectodermal origin. Approximatively 200
different conditions of ED are known in humans. [1–3]. Outside
humans, spontaneous forms of EDs have been reported extensively
in cattle [4–7] and dogs [8–10].
EDs are caused by mutations in genes belonging to different
pathways. There are more than 30 genes associated with EDs.
Many of these genes are in the ectodyplasin, NFkB, and WNT
pathways [1–3,11,12]. The NFkB family comprises transcription
factors involved in the regulation of diverse cellular processes,
including inflammation, innate/adaptive immunity, and cell
survival during development [13]. In nonstimulated cells, some
NFkB transcription factors are bound to inhibitory IkB proteins
and are thereby sequestered in the cytoplasm. Activation occurs
upon phosphorylation and subsequent degradation of the IkB
complex. Two protein kinases with a high degree of sequence
similarity, IKKa (approved symbol: CHUK) and IKKb (approved
symbol: IKBKB), mediate phosphorylation of IkB proteins and
represent a convergence point for most signal transduction
pathways leading to NFkB activation. Most of the IKK complexes
also contain a regulatory subunit called IKKc or NFkB essential
modulator (NEMO), which is encoded by the X-chromosomal
IKBKG gene [13].
Mutations in the IKBKG gene can lead to various, clinically
distinct EDs in humans. Hypomorphic mutations typically
affecting the C-terminal region of the encoded protein lead to
the X-chromosomal recessive hypohidrotic or anhidrotic ectoder-
mal dysplasia with immune deficiency (HED-ID, OMIM
#300291) [14]. Other rare types of mutations in the IKBKG gene
lead to isolated immune deficiencies (OMIM #300584, #300636,
and #300640) [15]. Most known variants including the presumed
complete loss-of-function variants in the human IKBKG gene lead
to an ED with characteristic clinical features termed incontinentia
pigmenti (IP, OMIM #308300) [16,17].
IP in humans is a rare disorder of several ectodermal tissues
including hair, skin, teeth, nails, and eyes. The condition is
transmitted as an X-linked dominant trait with intrauterine
lethality of the affected, hemizygous males. Females heterozygous
for IKBKG mutations have clinical features of IP and demonstrate
skewed X-inactivation. An increased risk of cell death in cells
expressing the abnormal IKBKG gene results in negative selection,
leaving more cells expressing the wild type IKBKG to survive and
proliferate. This is reflected in the clinical course of IP, where
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patients show skin blistering and severe skin lesions immediately
after birth. In later stages, most cells expressing the mutant X-
chromosome will be eliminated and the skin symptoms largely
resolve. Adult IP patients show characteristic patterns of hyper-
pigmentation, which follow Blaschko’s lines [18]. A number of
mutations in IKBKG have been identified to cause IP in humans.
The most common mutation is a deletion of exons 4 to 10, which
are flanked by two MER67B repeat sequences [16,17].
We have identified horses that show a phenotype with many
similarities to human IP. The aim of this study was to elucidate the
underlying genetic defect in these horses.
Results
Phenotypic description
We observed a family of horses, in which several mares
developed signs of a skin disorder reminiscent of human IP.
Cutaneous manifestations in affected horses included the devel-
opment of pruritic, exudative lesions soon after birth. These
developed into wart-like lesions and areas of alopecia. Occasion-
ally, we observed hair re-growth with a wooly appearance.
Affected horses also had streaks of darker and lighter coat
coloration from birth. These cutaneous manifestations followed
the lines of Blaschko. Other clinical symptoms included anomalies
of tooth, hoof and ocular development (Figure 1).
Pedigree analysis
All the affected mares belonged to the same family and were
descendants of one affected founder mare. All affected animals
were female, and two of them had reported abortions. Thus, the
pedigree was compatible with an X-chromosomal dominant mode
of inheritance (Figure 2).
Mutation identification
We sequenced the whole genome of one affected mare in order
to get a comprehensive overview of all sequence variants (animal
II-8 in Figure 2). We collected 225 million 26100 bp paired-end
reads from a shotgun fragment library corresponding to roughly
196 coverage of the genome. We called SNPs and indel variants
with respect to the EquCab 2 reference genome and identified
approximately 7.8 million variants in total. The observed
phenotype and alleged mechanism of transmission of the condition
prompted us to focus exclusively on heterozygous variants on the
X chromosome. The data contained 557 X-chromosomal non-
synonymous variants. We hypothesized that the mutant allele at
the causative variant should be completely absent from the general
horse population. Therefore, we compared the variants in the IP
affected horse with the genomes of 44 control horses from 11
breeds that had been sequenced in the course of other projects.
This filtering step resulted in 33 private and non-synonymous X-
chromosomal variants in the IP affected horse (Table 1).
We screened these results for variants in plausible functional
candidate genes and noticed a heterozygous c.184C.T mutation
in the IKBKG gene. This variant is a nonsense variant, predicted to
result in a premature stop codon, which truncates more than 85%
of the protein (p.Arg62*). We confirmed the co-segregation of the
variant with the phenotype in 3 affected and one non-affected
horse of the family by Sanger sequencing (Figure 3).
Transcript analysis
The equine IKBKG mRNA predictions from the NCBI and
ENSEMBL databases were significantly different from each other
and also did not align well with the human IKBKG mRNA
sequence. Therefore, we determined an experimental equine
IKBKG mRNA sequence from an RT-PCR product. We deposited
this sequence in the EMBL/Genbank/DDBJ databases under
accession number KF471022. Aligning this sequence to the
EquCab 2 reference genome sequence confirmed that the equine
IKBKG gene is similar to the other known mammalian orthologs
and contains nine coding exons spread over ,14 kb of genomic
DNA on the X chromosome. Exon 4 lies within an unsequenced
gap region of genomic DNA and its exact position could not be
ascertained. All available exon/intron boundaries conformed to
the AG/GT splicing consensus sequences (Table 2).
Comparison of the equine IKBKG mRNA to other species
showed high levels of homology between a number of different
species ranging from 90% identity with Bos taurus and Homo sapiens
to 96% with the Southern white rhinoceros (Ceratotherium simum
simum). Similarly, the predicted protein sequence showed a high
level of identity between species: 90% with Bos taurus, 92% with
Homo sapiens and 97% with Ceratotherium simum simum.
Figure 1. Phenotype of an affected horse. Brindled pigmentation
and patches of hairless skin are visible. The hairless skin probably
represents scarring alopecia following the different stages of skin
lesions described. The patterns of hyperpigmentation and the skin
alterations follow the lines of Blaschko. The depicted horse corresponds
to animal III-10 in the pedigree shown in Figure 2.
doi:10.1371/journal.pone.0081625.g001
Figure 2. Pedigree of the horse family presented in this study.
The affected animals are shown as filled symbols. Non-affected animals
are shown with open symbols. Males are shown as squares and females
as circles; aborted foals (sex unknown) are shown as small black circles.
The whole genome re-sequencing experiment was performed with
DNA from animal II-8. The horse II-2 was killed in an accident and III-2
was born dead. Both deceased animals showed clear signs of IP.
doi:10.1371/journal.pone.0081625.g002
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Discussion
In this study, we identified an IKBKG nonsense mutation in a
family of horses perfectly co-segregating with a phenotype
resembling human IP. The most recognizable symptoms of IP
are skin lesions evolving over time. In our horses, we early on
observed the erythema and vesicles, and the verrucous hyperker-
atotic papules typical of preliminary phases of the disease (‘‘phase
1’’ and ‘‘phase 2’’ [19]). In adult animals the whorls and streaks of
pigmentation following the lines of Blaschko and pale, hairless,
atrophic patches and/or hypopigmentation were visible, which
corresponded well to ‘‘phase 3’’ and ‘‘phase 4’’ of human IP [19].
The X-chromosomal dominant inheritance of the equine IP
phenotype further supported our hypothesis that the equine
phenotype was genetically homologous to human IP.
Using a whole genome sequencing approach we detected almost
8 million variants in an affected horse compared to the equine
genome reference sequence. By focusing on private X-chromo-
somal heterozygous non-synonymous variants, the initial daunting
number of variants shrank to a much more manageable 33.
Only one of these variants was located in a plausible candidate
gene for IP, the IKBKG gene. Mutations in the IKBKG gene have
been shown to result in an IP phenotype in humans and mice
[16,20,21]. In humans a large number of different mutations
causing IP in humans have been reported [22–26]. A frequent
recurrent deletion of exons 4 to 10 was found to account for more
than 80% of all human IP cases [16,17,23]. An identical mutation
to that identified in the studied family of horses has also been
identified in a human patient with IP [17]. The c.184C.T
transition identified in both cases occurs within a CpG dinucle-
otide. Transitions within the CpG dinucleotide account for
approximately 23% of all single base pair substitutions causing
human genetic disease [27] and are thought to occur due to
spontaneous deamination of the methylated cytosine within the
dinucleotide. It is likely that the mutation found in our horse
family occurred by the same mechanism. Although we have not
perfomed any functional validation of the equine variant, the
human-horse comparative data strongly suggest that we indeed
identified the causative variant for the observed phenotype in
horses and the genetic findings further confirm that this is indeed
an equine form of IP truly homologous to the human condition
In retrospect, we have to admit that we were lucky with our
methodological approach. As the horse genome reference
sequence and its annotation are in a preliminary draft status,
there are many genes including the IKBKG gene, which are
currently not correctly annotated. If the causative variant in the IP
affected horses had been located e.g. in exon 4, which is currently
not contained in the genomic reference sequence or in one of the
later exons, which are not all correctly annotated, our whole
genome sequencing experiment would have failed to yield the
causative variant. This clearly emphasizes the need for continuous
updating and improving of genome reference sequences, which
are an enormously important asset in current veterinary genetics.
In conclusion, we have identified a nonsense variant in the
equine IKBKG gene as most likely causative for a hereditary
ectodermal dysplasia in horses. A mutation event at the
homologous nucleotide position has independently occurred in a
human family segregating for IP. Thus, the genetic findings in
humans and horses mutually corroborate the causality of the
variant and confirm that horses with this genetic defect are a
valuable large animal model for human IP.
Materials and Methods
Ethics statement
All animal experiments were performed according to the local
regulations. The horses in this study were examined with the
consent of their owners. The experiments were approved by the
ethical review committee of Newcastle University (ID 272).
Animals
We used 3 female IP cases (II-6, II-8, III-10) and one female
control horse (III-7) from the family depicted in Figure 2.
Phenotypes were assigned by visual inspection of the skin
pigmentation and hair quality. We additionally used 44 unrelated
horses from 11 breeds as controls in this study. We isolated
Table 1. Summary of the whole genome sequencing experiment.
Filtering step Number of variants
Total variants in the whole genomea 7,807,149
Heterozygous variants in the whole genome 4,969,029
Heterozygous variants on the X-chromosome 191,844
Non-synonymous heterozygous variants on the X-chromosome 557
Non-synonymous heterozygous variants on the X-chromosome that were absent from 44 other horse genomes 33
aVariants were called with respect to the reference genome (EquCab 2) from a Thoroughbred horse.
doi:10.1371/journal.pone.0081625.t001
Figure 3. Sanger sequencing of the IKBKG:c.184C.T variant.
Electropherograms of a homozygous wildtype and a heterozygous
mare are shown. The reading frame and position of the nonsense
variant are indicated. The variant is chrX:122,833,887C.T with respect
to the EquCab 2 genome reference sequence.
doi:10.1371/journal.pone.0081625.g003
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genomic DNA samples from hair roots or EDTA blood samples
with the Nucleon Bacc2 kit (GE Healthcare).
Whole genome sequencing of an affected mare
We prepared a fragment library with 300 bp insert size from
animal II-8 (Figure 2) and collected one lane of illumina
HiSeq2000 paired-end reads (26100 bp). We obtained a total of
453,107,102 reads or roughly 196 coverage. We mapped the
reads to the Equcab 2.0 reference genome with the Burrows-
Wheeler Aligner (BWA) version 0.5.9-r16 [28] with default settings
and obtained 440,799,216 (92.8%) uniquely mapping reads. After
sorting the mapped reads by the coordinates of the sequence with
Picard tools, we labeled the PCR duplicates also with Picard tools
(http://sourceforge.net/projects/picard/). We used the Genome
Analysis Tool Kit (GATK version 0591, [29]) to perform local
realignment and to produce a cleaned BAM file. Variant calls
were then made with the unified genotyper module of GATK. For
variant calling we used only reads with mapping quality of $30
and bases with quality values $20. The variant data output file
obtained in VCF format 4.0 was filtered for high quality SNPs
using the variant filtering module of GATK. The filtering was
done as explained in the GATK best practice manual 3.0. The
snpEFF software [30] together with the EquCab 2.0 annotation
was used to predict the functional effects of detected variants.
Sanger sequencing
We used Sanger sequencing to confirm the illumina sequencing
results and to verify the association of the mutation within family.
For these experiments we amplified PCR products using
AmpliTaqGold360Mastermix (Applied Biosystems). PCR prod-
ucts were directly sequenced on an ABI 3730 capillary sequencer
(Applied Biosystems) after treatment with exonuclease I and
shrimp alkaline phosphatase. We analyzed the sequence data with
Sequencher 5.1 (GeneCodes).
Gene analysis
The human IKBKG transcript variant 3 mRNA (accession:
NM_003639.3) was used as query in cross-species BLAST
searches against the horse genome assembly. Two publicly
available equine IKBKG mRNA predictions show striking differ-
ences to the human sequence and are most likely not correct
(LOC100058432, accession XM_001495456.3; ENSE-
CAT00000022050.1). We therefore determined an experimental
equine mRNA sequence (see above), which is available under
accession KF471022. The genomic structure of the equine IKBKG
gene was determined by aliging this experimental mRNA
sequence to the EquCab 2.0 reference genome assembly using
the Spidey program (www.ncbi.nlm.nih.gov/spidey).
Transcript analysis
A skin biopsy from a control horse was finely minced and
homogenized using the FastPrep system and lysing matrix D (MP
Biomedical). Total RNA was then extracted using Trizol, DNase
treated and quantified. One mg total RNA was then reverse
transcribed using an oligo (dT)25 primer and Superscript II (Life
Technologies) according to the manufacturer’s instructions. PCR
was then performed on the cDNA using oligonucleotide primers
NEMO5 (59-ACCCTGACTTGTTGGATGAGC-39) and
NEMO3 (59-ACAGGCAGCCCTACTCGATG-39) and the High
Fidelity PCR system (Roche) using the following PCR cycle: 95uC
2 min followed by 35 cycles of 95uC 45 sec, 60uC 30 sec, 72uC
2 min followed by a final extension of 10 min at 72uC. The
resulting PCR product was then sequenced with the same
oligonucleotide primers used for PCR and the additional primers,
NEMOSEQ1 (59-ACGTGCTGGGTGAAGAGTC-39), NEMO-
SEQ1R (59-CCAGACAACGCTGGAAGG-39) and NEMO-
SEQ2 (59-ACGTGCAGGTGGACCAGC-39) using BigDye v3.1
(Applied Biosystems) and sequenced on an ABI 3100 genetic
analyser (Applied Biosystems).
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Table 2. Exons of the equine IKBKG gene.
Exona Startb Stopb Length (bp) Prec. intron Exon start Exon end Subseq. intron
2 ,122,833,704 122,833,890 .187 n.d. CCGAG gtgag
3 122,837,191 122,837,402 212 gccag ATGCC AGCAG gtagc
4 n.d. n.d. 119 n.d. CAGAT GGCAG n.d.
5 122,844,285 122,844,437 153 gccag GGCCC GAGAA gtgag
6 122,845,008 122,845,104 97 cttag GCGGA ACCGA gtgag
7 122,846,220 122,846,363 144 tccag GGAAT CCCAG gtgag
8 122,846,643 122,846,785 143 gccag GCGGA GCCAG gtggg
9 122,846,995 122,847,056 62 ctaag GATCG CCCAG gtgag
10 122,847,296 .122,847,438 .143 cccag CTCAC n.d.
aThe numbering of the exons corresponds to the situation in other mammals, which have an additional 59-untranslated exon.
bThe coordinates correspond to the X-chromosome of the EquCab 2.0 genome reference assembly.
doi:10.1371/journal.pone.0081625.t002
IKBKG Mutation in Horses
PLOS ONE | www.plosone.org 4 December 2013 | Volume 8 | Issue 12 | e81625
References
1. Garcı´a-Martı´n P, Herna´ndez-Martı´n A, Torrelo A (2013) Ectodermal
dysplasias: A clinical and molecular review. Actas Dermosifiliogr 104: 451–470.
2. Priolo M (2009) Ectodermal dysplasias: an overview and update of clinical and
molecular-functional mechanism. Am J Med Genet A 149A: 2003–2013.
3. Wright JT, Morris C, Clements SE, D’Souza R, Gaide O, et al. (2009)
Classifying ectodermal dysplasias: Incorporating the molecular basis and
pathways (Workshop II). Am J Med Genet A 149A: 2062–2067.
4. Dro¨gemu¨ller C, Distl O, Leeb T (2001) Partial deletion of the bovine ED1 gene
causes anhidrotic ectodermal dysplasia in cattle. Genome Res 11: 1699–1705.
5. Dro¨gemu¨ller C, Peters M, Pohlenz J, Distl O, Leeb T (2002) A single point
mutation within the ED1 gene disrupts correct splicing at two different splice
sites and leads to anhidrotic ectodermal dysplasia in cattle. J Mol Med 80: 319–
323.
6. Dro¨gemu¨ller C, Kuiper H, Peters M, Guionaud S, Distl O, et al. (2002)
Congenital hypotrichosis with anodontia in cattle: a genetic, clinical and
histological analysis. Vet Dermatol 13: 307–313.
7. Seeliger F, Dro¨gemu¨ller C, Tegtmeier P, Baumga¨rtner W, Distl O, et al. (2005)
Ectodysplasin-1 deficiency in a German Holstein bull associated with loss of
respiratory mucous glands and chronic rhinotracheitis. J Comp Pathol 132:346–
349.
8. Casal ML, Scheidt JL, Rhodes JL, Henthorn PS, Werner P (2005) Mutation
identification in a canine model of X-linked ectodermal dysplasia. Mamm
Genome 16: 524–531.
9. Dro¨gemu¨ller C, Karlsson EK, Hyto¨nen MK, Perloski M, Dolf G, et al. (2008) A
mutation in hairless dogs implicates FOXI3 in ectodermal development. Science
321: 1462.
10. Olivry T, Linder KE, Wang P, Bizikova P, Bernstein JA, et al. (2012) Deficient
plakophilin-1 expression due to a mutation in PKP1 causes ectodermal
dysplasia-skin fragility syndrome in Chesapeake Bay retriever dogs. PLoS One
7: e32072.
11. Mikkola ML (2009) Molecular aspects of hypohidrotic ectodermal dysplasia.
Am J Med Genet A 149A: 2031–2036.
12. Cluzeau C, Hadj-Rabia S, Jambou M, Mansour S, Guique P, et al. (2011) Only
four genes (EDA1, EDAR, EDARADD and WNTA10A) account for 90% of
hypohidrotic/anhidrotic ectodermal dysplasia cases. Hum Mutat 32: 70–72.
13. Ha¨cker H, Karin M (2006) Regulation and function of IKK and IKK related
kinases. Sci STKE 2006: re13.
14. Zonana J, Elder ME, Schneider LC, Orlow SJ, Moss C, et al. (2000) A novel X-
linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is
allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO).
Am J Hum Genet 67: 1555–1562.
15. Niehues T, Reichenbach J, Neubert J, Gudowius S, Puel A, et al. (2004) Nuclear
factor kappaB essential modulator-deficient child with immunodeficiency yet
without anhidrotic ectodermal dysplasia. J Allergy Clin Immunol 114: 1456–
1462.
16. Smahi A, Courtois G, Vabres P, Yamaoka S, Heuertz S, et al. (2000) Genomic
rearrangement in NEMO impairs NF-kappaB activation and is a cause of
incontinentia pigmenti. Nature 405: 466–472.
17. Aradhya S, Woffendin H, Jakins T, Bardaro T, Esposito T, et al. (2001). A
recurrent deletion in the ubiquitously expressed NEMO (IKK-c) gene accounts
for the vast majority of incontinentia pigmenti mutations. Hum Mol Genet 10:
2171–2179.
18. Ehrenreich M, Tarlow MM, Godlewska-Janusz E, Schwartz RA (2007)
Incontinentia pigmenti (Bloch-Sulzberger syndrome): a systemic disorder. Cutis
79: 355–362.
19. Berlin AL, Paller AS, Chan LS (2002) Incontinentia pigmenti: a review and
update on the molecular basis of pathophysiology. J Am Acad Dermatol 47:
169–187.
20. Makris C, Godfrey VL, Krahn-Senftleben G, Takahashi T, Roberts JL, et al.
(2000) Female mice heterozygous for IKK gamma/NEMO deficiencies develop
a dermatopathy similar to the human X-linked disorder incontinentia pigmenti.
Mol Cell 5: 969–979.
21. Schmidt-Supprian M, Bloch W, Courtois G, Addicks K, Israel A, et al. (2000)
NEMO/IKK gamma-deficient mice model incontinentia pigmenti. Mol Cell 5:
981–992.
22. Fusco F, Bardaro T, Fimiani G, Mercadante V, Miano MG, et al. (2004)
Molecular analysis of the genetic defect in a large cohort of IP patients and
identification of novel NEMO mutations interfering with NF-kappaB activation.
Hum Mol Genet 13: 1763–1773.
23. Fusco F, Pescatore A, Bal E, Ghoul A, Paciolla M, et al. (2008) Alterations of the
IKBKG locus and diseases: an update and a report of 13 novel mutations. Hum
Mutat 29: 595–604.
24. Lee NC, Huang CH, Hwu WL, Chien YH, Chang YY, et al. (2009)
Pseudogene-derived IKBKG gene mutations in incontinentia pigmenti. Clin
Genet 76: 417–419.
25. Fryssira H, Kakourou T, Valari M, Stefanaki K, Amenta S, et al. (2011)
Incontinentia pigmenti revisited. A novel nonsense mutation of the IKBKG gene.
Acta Paediatr 100: 128–133.
26. Fusco F, Paciolla M, Napolitano F, Pescatore A, D’Addario I, et al. (2012)
Genomic architecture at the Incontinentia Pigmenti locus favours de novo
pathological alleles through different mechanisms. Hum Mol Genet 21: 1260–
1271.
27. Krawczak M, Ball EV, Cooper DN (1998). Neighbouring-nucleotide effects on
the rates of germ-line single-base-pair substitution in human genes. Am J Hum
Gen 63: 474–488.
28. Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics 25: 1754–1760.
29. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, et al. (2010) The
genome analysis toolkit: a MapReduce framework for analyzing next-generation
DNA sequencing data. Genome Res 20: 1297–1303.
30. Cingolani P, Platts A, Coon M, Nguyen T, Wang L, et al. (2012) A program for
annotating and predicting the effects of single nucleotide polymorphisms,
SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2;
iso-3. Fly 6: 80–92.
IKBKG Mutation in Horses
PLOS ONE | www.plosone.org 5 December 2013 | Volume 8 | Issue 12 | e81625
